Events - Pharvaris N.V.

Upcoming Events

Oct 15 - Oct 18, 2026

JSA/WAO/APAPARI Joint Congress 2026

Add to Outlook

Add to Google Calendar

Oct 23 - Oct 25, 2026

2026 HAEi Regional Conference Americas

Add to Outlook

Add to Google Calendar

Oct 23 - Oct 25, 2026

The XXXVIII National Congress of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC)

Add to Outlook

Add to Google Calendar

Oct 28 - Oct 31, 2026

Spanish Society of Allergology and Clinical Immunology (SEAIC) 2026

Add to Outlook

Add to Google Calendar

Nov 9, 2026 1:30 PM EST

Guggenheim 3rd Annual Healthcare Innovation Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Dec 2, 2026 10:00 AM EST

9th Annual Evercore Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Past Events

Jun 12 - Jun 15, 2026

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial 1.2 MB

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant 712.7 KB

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema 394.9 KB

Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule 174.5 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial 262.8 KB

RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 254.2 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 202.8 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema 200.7 KB

Jun 9, 2026

World Orphan Drug Congress (WODC) USA 2026

Supporting Materials

From Symptoms to Decisions: How Patient-Reported Outcomes Shape Trustworthy Clinical Evidence 13.9 MB

May 28 - May 31, 2026

2026 Eastern Allergy Conference (EAC)

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results Of The CHAPTER-1 Open-Label Extension Study 424.9 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.1 KB

May 17 - May 20, 2026

ISPOR 2026

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 238.4 KB

May 7 - May 9, 2026

2026 EAACI Beijing Allergy School & PUMCH Allergy Symposium

Supporting Materials

Efficacy and Safety of On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Phase 3 RAPIDe-3 Trial Results 490.1 KB

Apr 17 - Apr 19, 2026

CIIC Spring 2026 Conference

Supporting Materials

Evaluating Safety Margins of the Use of Deucrictibant Extended-Release Tablet in Combination with Deucrictibant Immediate-Release Capsule 279.7 KB

On-Demand Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant Immediate-Release Capsule: Efficacy and Safety Results of the Phase 3 RAPIDe-3 Trial 364.7 KB

Mar 27 - Mar 28, 2026

2026 Global Angioedema Leadership Conference

Supporting Materials

Results of the Phase 3 RAPIDe-3 Study of Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 283.7 KB

End of Progression of Hereditary Angioedema Attacks with Oral Deucrictibant Immediate-Release Capsule: RAPIDe-3 Phase 3 Trial 270.9 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema 223.9 KB

Lived Patient Experiences of Hereditary Angioedema Based on Attacks and Associated Symptoms: An Innovative Conceptual Model 375.8 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 233.3 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema (presentation) 560 KB

Mar 19 - Mar 21, 2026

Italian Network for Hereditary and Acquired Angioedema (ITACA) 5th ITACA National Congress

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 450.9 KB

Feb 27 - Mar 2, 2026

American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting

Supporting Materials

A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema 424.5 KB

Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks 416.5 KB

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 500.3 KB

Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study 593.7 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 446.9 KB

Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 523.1 KB

Feb 1 - Feb 5, 2026

Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 221.7 KB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page